Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | WNT3 | P56703 | 1/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23183608 | 0.92 | HRH3 (0.42) | HRH3TSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18911334 | 0.88 | RECQL (0.41) | HRH3TSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18915159 | 0.84 | L3MBTL1 (0.49) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18915264 | 0.82 | ROCK2 (0.40) | — | |
| SCHEMBL18915160 | 0.82 | CXCR4 (0.36) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18915037 | 0.81 | HTR2C (0.41) | WNT3SFRP1CXCR4 | |
| SCHEMBL12629018 | 0.81 | KMT2A (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL18916035 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTCXCR4MAPT | |
| SCHEMBL18894254 | 0.78 | ALDH1A1 (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18915974 | 0.76 | KDM4E (0.52) | SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| WO-2017089847-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885TSHR 981/4885SMN1; SMN2 880/4885 |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885TSHR 981/4885SMN1; SMN2 880/4885 |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885TSHR 981/4885SMN1; SMN2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.